Returns as of 09/24/2020. © American Consumer News, LLC dba MarketBeat® 2010-2020. Shares of HEXO Corp. (NASDAQ:HEXO) have earned a consensus rating of “Hold” from the twenty-one research firms that are currently covering the company, MarketBeat reports. at Zacks.com Wed, Sep. 02. Sign-up to receive the latest news and ratings for HEXO and its competitors with MarketBeat's FREE daily newsletter. Ten research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has assigned a buy rating to the company. This change lagged the S&P 500's daily gain of … HEXO stock was sold by a variety of institutional investors in the last quarter, including TD Asset Management Inc., and Bank of America Corp DE. Learn more. The company has 38 patents. Shares of HEXO can be purchased through any online brokerage account. It also cut its price target on the shares nearly in half, from 1.90 Canadian dollars ($1.43) to CA$1 ($0.75). Vote “Outperform” if you believe HEXO will outperform the S&P 500 over the long term. Cannabis ETFs: A Good Way to Get Exposure to the Cannabis Sector? The two are collaborating on a line of such drinks.
HEXO has a market capitalization of $312.55 million. In the above graph, you can see that analysts’ consensus target price has seen downward momentum since September 2019. The company's average rating score is 1.58, and is based on 1 buy rating, 9 hold ratings, and 9 sell ratings. See you at the top! U.S. States With Legal Recreational Marijuana Use in 2020, Investment Radar — Top CBD Stocks to Watch, Analysts favor the “hold” rating for Cronos Group. 3 Oversold Stocks That Could Bounce Back in a Hurry, Papa Johns (NASDAQ: PZZA) Stock Pullback Opportunities Here, Buy CarMax (NYSE:KMX) On Post-Earnings Weakness, Pfizer (NYSE:PFE) Stock: A Strong Option for Dividend Investors. It provides its products under the HEXO and Hydropothecary brand names. The average 1-year price […] HEXO has received 123 “outperform” votes. Despite Recent 7-Figure Raises, Cannabis Investments Remain Slow In 2020. at Benzinga Fri, Aug. 21. The stock fell 2.1% from the previous day’s closing price.
You may vote once every thirty days. Identify stocks that meet your criteria using seven unique stock screeners. The average 12-month […]
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
(Add your “outperform” vote. Learn everything you need to know about successful options trading with this three-part video course.
Some companies that are related to HEXO include Knight Therapeutics (GUD), Aurora Cannabis (ACB), HLS Therapeutics (HLS), Amryt Pharma (AMYT), Benchmark (BMK), OrganiGram (OGI), ICC Labs (ICC), Shield Therapeutics (STX), ESSA Pharma (EPI), Green Organic Dutchman (TGOD), cbdMD (YCBD), WeedMD (WMD), Delta 9 Cannabis (NINE), Diurnal Group (DNL) and Venture Life Group (VLG). The target price has fallen by 77.6% since September. HEXO Corp () Stock Market info Recommendations: Buy or sell HEXO stock? Wendy’s (NYSE: WEN) Stock a Pandemic and Recovery Play, BioXCel Therapeutics (NASDAQ:BTAI) A Hot Buy That Confuses Analysts, Rite Aid Is a Cautious Buy Ahead of Earnings, The Steelcase (NYSE:SCS) 4% Dividend Is Worth Your Time, 8 Stocks That Robinhood Investors Got Right, 7 Stocks That Will Help You Forget About the Fed, 7 Stocks That Don’t Care Who Wins the Election, 7 Semiconductor Stocks to Power Your Portfolio, 7 Gold Stocks to Buy Before the Fed Changes Its Mind, 8 Consumer Staples Stocks That Offer Good Value, 6 Stocks Riding the Coattails of Nikola Motor, 8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor, Receive Analysts' Upgrades and Downgrades Daily. Fundamental company data provided by Morningstar and Zacks Investment Research. MarketBeat's community ratings are surveys of what our community members think about HEXO and other stocks. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Stock Advisor launched in February of 2002. Learn more. The company can be reached via phone at 844-406-1852. HEXO CORP. analysts consensus, targets, ratings and recommendations | Toronto Stock Exchange: HEXO | Toronto Stock Exchange The company serves medical and adult-use markets. Please log in to your account or sign up in order to add this asset to your watchlist. All rights reserved. The company is focused on the market for cannabis-infused beverages, due in no small part to a joint venture it operates with brewery giant Molson Coors (NYSE:TAP).
View analyst ratings for HEXO. The company’s weak first-quarter performance in December, concerns about dilution with new stock offerings, and MediPharm’s lawsuit might have prompted analysts’ to lower their target price.